共 50 条
- [1] Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple MyelomaCLINICAL LABORATORY, 2018, 64 (04) : 551 - 558Meddour, YanisRahali, Momahed C.Belakehal, Salah E.Ardjoun, Fatma Z.Chaib, SamiaDjidjik, Reda
- [2] Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myelomaHAEMATOLOGICA, 2023, 108 (11) : 2894 - 2912Richardson, Paul G.Durie, Brian G.Rosinol, LauraMateos, Maria-VictoriaDispenzieri, AngelaMoreau, PhilippeKumar, ShajiRaje, NoopurMunshi, NikhilLaubach, Jacob P.O'Gorman, PeterO'Donnell, ElizabethVoorhees, PeterFacon, ThierryBlade, JoanLonial, SagarPerrot, AuroreAnderson, Kenneth C.
- [3] Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myelomaBRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (03) : E38 - E41Kawano, YawaraHata, HiroyukiTakashio, SeijiTsujita, KenichiUeda, MitsuharuMatsuoka, Masao
- [4] Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma PatientsBLOOD, 2014, 124 (21)Korde, NehaDosani, TalibSimakova, OlgaMailankody, ShamCostello, ReneRoschewski, MarkYuan, ConstanceStetler-Stevenson, MaryaliceFigg, William D.Landgren, OlaMaric, Irina
- [5] Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (12): : 797 - 803Kaufman, Jonathan L.Mina, RobertoShah, Jatin J.Laubach, Jacob P.Nooka, Ajay K.Lewis, ColleenGleason, ChariseSharp, CathyHarvey, R. DonaldHeffner, Leonard T.Richardson, PaulLonial, SagarOrlowski, Robert Z.
- [6] Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple MyelomaJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) : 2901 - +Costa, Luciano J.Chhabra, SaurabhMedvedova, EvaDholaria, Bhagirathbhai R.Schmidt, Timothy M.Godby, Kelly N.Silbermann, RebeccaDhaka, BinodBal, SusanGid, SmithD'Souza, AnitaHall, AricHardwick, PamelaOmel, JamesCornell, Robert F.Had, ParameswaranCallander, Natalie S.
- [7] CLINICAL IMPACT OF THE PLASMA LENALIDOMIDE CONCENTRATION AND THE ANALYSIS OF ANTI-TUMOR IMMUNE RESPONSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE AND DEXAMETHASONE THERAPYHAEMATOLOGICA, 2017, 102 : 795 - 795Kobayashi, T.Miura, M.Niioka, T.Fujioka, Y.Abumiya, M.Ikeda, S.Yoshioka, T.Kameoka, Y.Nishikawa, H.Takahashi, N.
- [8] Prediction of Response and Progression in Multiple Myeloma With Serum Free Light Chains Assay: Corroboration of the Serum Free Light Chain Response DefinitionsCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (01): : E10 - E13Khoriaty, RamiHussein, Mohamad A.Faiman, BethKelly, MeganKalaycio, MattBaz, Rachid
- [9] Daratumumab plus Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFINCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E353 - E354Voorhees, PeterKaufman, Jonathan L.Laubach, JacobSborov, DouglasReeves, BrandiRodriguez, CesarChari, AjaiSilbermann, RebeccaCosta, LucianoAnderson, LarryNathwani, NityaShah, NinaEfebera, YvonneCostello, CaitlinJakubowiak, AndrzejWildes, TanyaOrlowski, Robert Z.Shain, Kenneth H.Cowan, AndrewMurphy, SeanLutska, YanaPei, HuilingUkropec, JonVermeulen, Jessicade Boer, CarlaHoehn, DanielaLin, ThomasRichardson, Paul G.
- [10] PRELIMINARY STUDY OF CLINICAL VALIDATION OF THE RESPONSE CRITERIA PROPOSED BY THE INTERGROUPE FRANCOPHONE OF MYELOMA FOR PATIENTS WITH MULTIPLE MYELOMAHAEMATOLOGICA, 2019, 104 : 400 - 400Melero Lopez, D.Liria Gonzalez, IBarbosa de Carvalho, N.Moreira Pais, T.Tejedor Diaz, C.Puerta Fonolla, P.